Turbulence Ahead For Indian Firms Caught In Russia-Ukraine Conflict
Dr Reddy's, Sun, Glenmark Have Interests In Region
Leading Indian firms with operations in the war zone stare at uncertainties and disruptions as sanctions by the US and Western allies threaten to choke the Russian economy.
You may also be interested in...
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.
Efforts are being made across the European off-patent community to bolster the supply chain and ensure access to medicines in Ukraine, says the generics and biosimilars industry association, Medicines for Europe. It has urged the EU to take a leading role in coordinating supplies through the new emergency response body, HERA.